The approval follows the December 2024 priority review designation for this perioperative immunotherapy regimen for patients fighting muscle-invasive bladder cancer (MIBC).
AstraZeneca has secured another expansion of its Imfinzi for use in cancer patients before and after surgery. | Imfinzi is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback